Bullous Pemphigoid
Autoimmune blistering disease causing intensely itchy, tense fluid-filled blisters in older adults.
Emergency Management: Sepsis from generalized secondary bacterial skin infection requires IV antibiotics and admission.
An autoimmune, chronic, subepidermal blistering skin disease characterized by tense bullae on normal or erythematous skin. It primarily affects the elderly.
Detailed Overview
BP is the most common autoimmune blistering disease. IgG autoantibodies target the hemidesmosomal proteins BP180 and BP230 at the dermal-epidermal junction. This triggers complement activation and neutrophil infiltration, leading to subepidermal split. The blisters are tense, non-scarring, and accompanied by severe pruritus. Unlike pemphigus vulgaris, mucous membranes are rarely involved.
Epidemiology & Demographics
Incidence is 10-40 per million annually. Peak onset is in individuals over age 60, heavily skewed towards octogenarians.
Etiological Mechanism
Autoimmune production of IgG against hemidesmosomes. Triggers may include medications, trauma, or UV radiation.
Primary Causes
Primary: Idiopathic autoimmune. Secondary (drug-induced): DPP-4 inhibitors (gliptins), furosemide, penicillamine, PD-1 inhibitors.
IgG autoantibodies bind BP180 (type XVII collagen) and BP230 in the hemidesmosomes of the basement membrane zone. This antigen-antibody complex activates the classical complement pathway. C3a and C5a recruit eosinophils and neutrophils, which release proteases (elastase, MMP-9). These enzymes degrade the hemidesmosomes, causing a subepidermal split and formation of tense, robust blisters.
Diagnostic Criteria & Guidelines
Diagnosis requires clinical presentation of tense bullae, two biopsies (one for H&E showing subepidermal cleft with eosinophils, one for DIF showing linear IgG/C3 at the basement membrane), and positive serum ELISA for BP180/BP230 autoantibodies.
High-potency topical corticosteroids: Clobetasol propionate 0.05% cream applied directly to lesions twice daily (total body application if extensive). Systemic steroids for severe cases: Prednisone 0.5-1.0 mg/kg PO daily.
Second-Line & Adjunctive Therapy
For steroid-sparing or refractory disease: Methotrexate 10-15 mg PO weekly, Mycophenolate mofetil 1-2 g/day, or Doxycycline 100 mg BID combined with Niacinamide 500 mg TID.
Surgical & Procedural Management
None. Debridement of necrotic skin may be needed if infected.
Patient Counseling & Advice
Counsel patients that the disease is chronic but can go into remission. Warn about the risks of long-term oral steroids (osteoporosis, hyperglycemia).
Follow-Up & Monitoring Schedule
Monthly visits to titrate steroid dosing based on new blister formation. Monitor DEXA scan and HbA1c if on long-term prednisone.
Preventive Strategies
Avoid known drug triggers (e.g., specific DPP-4 inhibitors like vildagliptin/linagliptin).
Generally good with treatment, often remitting after 1-5 years. However, 1-year mortality can be up to 20-30% in frail, elderly patients due to infections or steroid complications.